Additionally, as an increasing number of targeted therapies are being developed, cfDNA analysis may be able to identify cancers eligible for personalized approaches (such as HER2 or BRAF targeted therapy or platinum-based chemotherapy for BRCA2 mutated PC). Here, ERBB2 is linked to cancer.